A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer

ABSTRACT

Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3–19), the progression-free survival was 2.9 months (95% CI, 1.9–3.6), the median overall survival was 8.2 months (95% CI, 4.9–10.5), and 1-year survival rate was 33% (95% CI, 21–45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

Keywords: :

• Platinum-based
• Clinical trial
• Lung cancer
• Epidermal growth factor receptor (EGFR)
• First-line therapy